Zydus Lifesciences Ltd

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd. is a global pharmaceutical company dedicated to innovation, research, development, manufacturing, and marketing of a diverse range of healthcare products. With a strong focus on generics, specialty formulations, and consumer wellness, Zydus has a significant market presence in India and international markets, including the US.

Key Financial Ratios of Zydus Lifesciences Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Zydus Lifesciences Ltd's P/E ratio (TTM) is 33.01, compared to the industry median of 30.91 and large cap median of 32.45.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Zydus Lifesciences Ltd's P/B ratio is 4.34, compared to the industry median of 3.69 and large cap median of 4.94.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Zydus Lifesciences Ltd's P/S ratio is 4.32, compared to the industry median of 3.74 and large cap median of 6.08.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Zydus Lifesciences Ltd's PEG ratio is 1.34.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Zydus Lifesciences Ltd's EV/EBITDA ratio is 14.14.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Zydus Lifesciences Ltd's ROE is 18.90%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Zydus Lifesciences Ltd's ROA is 16.17%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Zydus Lifesciences Ltd's ROCE is 21%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Zydus Lifesciences Ltd's operating margin is 31.22%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Zydus Lifesciences Ltd's net margin is 18.87%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Zydus Lifesciences Ltd's current ratio is 0.80.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Zydus Lifesciences Ltd's debt-to-equity ratio is 0.15.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Zydus Lifesciences Ltd's interest coverage ratio is 16.08.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Zydus Lifesciences Ltd's DPS is ₹1.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Zydus Lifesciences Ltd's EPS is 11.39.

(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1167.80. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1952 (as Cadila Laboratories)

• Headquarters: Ahmedabad, Gujarat

• Core Offerings: Generics, Specialty Formulations, Consumer Wellness, Biologics & Biosimilars, Vaccines

• Stock Listing: NSE (ZYDUSLIFE), BSE (532321)

• Promoter: Pankaj Patel / Cadila Healthcare Group

History of Zydus Lifesciences Ltd

Zydus Lifesciences was founded in 1952 as Cadila Laboratories. In 1995, Cadila Laboratories split, forming Cadila Healthcare Ltd. (later Zydus Lifesciences), which went public in 1996. The company expanded significantly through strategic acquisitions, including German Remedies and Alpharma, and ventured into biotechnology and vaccines. Notable milestones include launching India's first indigenously developed H1N1 vaccine in 2007 and the world's first biosimilar of Adalimumab in 2015. In 2022, Cadila Healthcare Ltd. was renamed Zydus Lifesciences Ltd., reflecting its diversified global healthcare identity.

Business Segments and Revenue Mix

• India Formulations: Focuses on branded generics across therapeutic areas like cardiovascular, gastrointestinal, women's health, and respiratory, leveraging a strong distribution network and patient access programs.

• US Formulations: Engages in the development and commercialization of generic and specialty products for the highly regulated US market, including complex generics and biosimilars.

• Consumer Wellness: Offers a diverse portfolio of over-the-counter (OTC) products, including health & hygiene, pain relief, and dietary supplements, marketed under popular brands like Sugarfree and Comfy.

• Emerging Markets & Europe: Exports a wide range of pharmaceutical products, covering generics and specialty formulations, to key markets in Africa, Asia, Latin America, and select European countries.

Key Personnel

Pankaj R. Patel (Chairman): A respected veteran in the Indian pharmaceutical industry, he has been instrumental in Zydus's growth, global expansion, and strong R&D focus, transforming it into a major player. Sharvil P. Patel (Managing Director): Leads the company's strategic direction and operations, driving innovation, digital transformation, and portfolio diversification, particularly in specialty and biologics segments.

Subsidiaries and Associate Companies

• Zydus Healthcare Limited

• Zydus Wellness Limited

• Zydus Animal Health and Investments Limited

• Zydus Pharmaceuticals (USA) Inc.

• Biochem Pharmaceutical Industries Limited

Corporate Actions

A 1:1 bonus issue was declared in July 2022. The company changed its name from Cadila Healthcare Ltd. to Zydus Lifesciences Ltd. in February 2022. Zydus Wellness, a subsidiary, acquired Heinz India's Complan and Glucon-D brands in 2018. Zydus also acquired certain brands from GlaxoSmithKline Asia Pvt. Ltd. (GSK) in 2020.

References

1. Annual Report FY23
2. Exchange Filings (NSE/BSE)
3. Investor Presentations (Q3 FY24, Q4 FY24)
4. Company Website (www.zyduslife.com)